{
    "doi": "https://doi.org/10.1182/blood.V118.21.3773.3773",
    "start_url": "https://ashpublications.org/blood/search-results?sort=Date+-+Oldest+First&f_ArticleTypeDisplayName=Meeting+Report&fl_SiteID=1000001&page=1953",
    "start_url_page_num": 1953,
    "is_scraped": "1",
    "article_title": "Distinct Characteristics of e13a2 versus e14a2 BCR-ABL Chronic Myeloid Leukemia under Upfront Treatment with Imatinib \u2013 an Analysis of the German CML Study IV, ",
    "article_date": "November 18, 2011",
    "session_type": "632. Chronic Myeloid Leukemia - Therapy: Poster III",
    "topics": [
        "bcr-abl tyrosine kinase",
        "imatinib mesylate",
        "leukemia, myelocytic, chronic",
        "measles-mumps-rubella vaccine",
        "polymerase chain reaction",
        "rna, messenger",
        "adverse event",
        "amino acids",
        "cytarabine",
        "disease remission"
    ],
    "author_names": [
        "Benjamin Hanfstein, MD",
        "Philipp Erben, MD",
        "Susanne Saussele, MD",
        "Michael Lauseker",
        "Ulrike Proetel, MD",
        "Sven Haag",
        "Susanne Schnittger, PhD",
        "Claudia Haferlach, MD",
        "Hans-Jochem Kolb, MD",
        "Stefan W. Krause, MD",
        "Christoph Nerl, MD",
        "Dominik Heim, MD",
        "Gabriela M. Baerlocher, MD",
        "Jo\u0308rg E. A. Schubert, MD",
        "Hermann Einsele, MD",
        "Mathias Ha\u0308nel, MD",
        "Jolanta Dengler, MD",
        "Christiane Falge, MD",
        "Lothar Kanz, MD",
        "Andreas Neubauer, MD",
        "Michael Kneba, MD",
        "Frank Stegelmann, MD",
        "Michael Pfreundschuh, MD",
        "Cornelius F. Waller, MD",
        "Markus Pfirrmann, PhD",
        "Jo\u0308rg Hasford, MD",
        "Wolf-Karsten Hofmann, MD",
        "Ru\u0308diger Hehlmann, MD",
        "Andreas Hochhaus, MD",
        "Martin C. Mu\u0308ller, MD",
        "for The German CML Study Group",
        "for The SAKK"
    ],
    "author_affiliations": [
        [
            "III. Medizinische Klinik, Medizinische Fakulta\u0308t Mannheim, Universita\u0308t Heidelberg, Mannheim, Germany, "
        ],
        [
            "III. Medizinische Klinik, Medizinische Fakulta\u0308t Mannheim, Universita\u0308t Heidelberg, Mannheim, Germany, "
        ],
        [
            "III. Medizinische Klinik, Medizinische Fakulta\u0308t Mannheim, Universita\u0308t Heidelberg, Mannheim, Germany, "
        ],
        [
            "Institut fu\u0308r Medizinische Informationsverarbeitung, Biometrie und Epidemiologie, Ludwig-Maximilians-Universita\u0308t Mu\u0308nchen, Mu\u0308nchen, Germany, "
        ],
        [
            "III. Medizinische Klinik, Medizinische Fakulta\u0308t Mannheim, Universita\u0308t Heidelberg, Mannheim, Germany, "
        ],
        [
            "III. Medizinische Klinik, Medizinische Fakulta\u0308t Mannheim, Universita\u0308t Heidelberg, Mannheim, Germany, "
        ],
        [
            "MLL, Mu\u0308nchner Leuka\u0308mie Labor, Mu\u0308nchen, Germany, "
        ],
        [
            "MLL, Mu\u0308nchner Leuka\u0308mie Labor, Mu\u0308nchen, Germany, "
        ],
        [
            "Medizinische Klinik und Poliklinik III, Klinikum der Universita\u0308t Mu\u0308nchen-Gro\u00dfhadern, Mu\u0308nchen, Germany, "
        ],
        [
            "Medizinische Klinik 5, Universita\u0308tsklinikum Erlangen, Erlangen, Germany, "
        ],
        [
            "Klinik fu\u0308r Ha\u0308matologie, Krankenhaus Mu\u0308nchen-Schwabing, Mu\u0308nchen, Germany, "
        ],
        [
            "Deptartment of Hematology, Universita\u0308tsspital Basel, Basel, Switzerland, "
        ],
        [
            "Universita\u0308tsklinik fu\u0308r Ha\u0308matologie, Inselspital Bern, Bern, Switzerland, "
        ],
        [
            "Abteilung fu\u0308r Ha\u0308matologie/Onkologie, Evangelisches Krankenhaus Hamm, Hamm, Germany, "
        ],
        [
            "Medizinische Klinik II, Universita\u0308tsklinikum Wu\u0308rzburg, Wu\u0308rzburg, Germany, "
        ],
        [
            "Klinik fu\u0308r Innere Medizin III, Klinikum Chemnitz, Chemnitz, Germany, "
        ],
        [
            "Innere Medizin V, Universita\u0308tsklinikum Heidelberg, Heidelberg, Germany, "
        ],
        [
            "Medizinische Klinik 5, Klinikum Nu\u0308rnberg Nord, Nu\u0308rnberg, Germany, "
        ],
        [
            "Innere Medizin II, Universita\u0308tsklinikum Tu\u0308bingen, Tu\u0308bingen, Germany, "
        ],
        [
            "Klinik fu\u0308r Ha\u0308matologie, Zentrum Innere Medizin, Philipps-Universita\u0308t Marburg, Marburg, Germany, "
        ],
        [
            "II. Medizinische Klinik und Poliklinik, Universita\u0308tsklinikum Schleswig-Holstein, Kiel, Germany, "
        ],
        [
            "Klinik fu\u0308r Innere Medizin III, Universita\u0308tsklinikum Ulm, Ulm, Germany, "
        ],
        [
            "Innere Medizin I, Universita\u0308tsklinikum des Saarlandes, Homburg, Germany, "
        ],
        [
            "Innere Medizin 1, Universita\u0308tsklinikum Freiburg, Freiburg, Germany, "
        ],
        [
            "Institut fu\u0308r Medizinische Informationsverarbeitung, Biometrie und Epidemiologie, Ludwig-Maximilians-Universita\u0308t Mu\u0308nchen, Mu\u0308nchen, Germany, "
        ],
        [
            "Institut fu\u0308r Medizinische Informationsverarbeitung, Biometrie und Epidemiologie, Ludwig-Maximilians-Universita\u0308t Mu\u0308nchen, Mu\u0308nchen, Germany, "
        ],
        [
            "III. Medizinische Klinik, Medizinische Fakulta\u0308t Mannheim, Universita\u0308t Heidelberg, Mannheim, Germany, "
        ],
        [
            "III. Medizinische Klinik, Medizinische Fakulta\u0308t Mannheim, Universita\u0308t Heidelberg, Mannheim, Germany, "
        ],
        [
            "Hematology/Oncology, Universita\u0308tsklinikum Jena, Jena, Germany"
        ],
        [
            "III. Medizinische Klinik, Medizinische Fakulta\u0308t Mannheim, Universita\u0308t Heidelberg, Mannheim, Germany, "
        ],
        [],
        []
    ],
    "first_author_latitude": "49.4924375",
    "first_author_longitude": "8.486733399999999",
    "abstract_text": "Abstract 3773 Introduction: The vast majority of chronic myeloid leukemia (CML) patients express a BCR-ABL fusion gene mRNA encoding a 210 kDa tyrosine kinase which is constitutively activated and hence the mainspring of leukemic transformation. Two typical mRNA variants exist that differ in the presence or absence of the 75 basepair BCR exon 14: the e13a2 (lacking exon 14, also known as \u201cb2a2\u201d) and the e14a2 BCR-ABL transcript (\u201cb3a2\u201d). The significance of the additional 25 amino acid residues of the e14a2 BCR-ABL oncoprotein was extensively studied in the pre-imatinib era. However, the influence of the BCR-ABL transcript variant on the individual disease phenotype and outcome remained controversial and is still undefined in the imatinib era. Patients and methods: A total of 1,104 patients (median age 52 years, range 16\u201385, 40% female) expressing typical BCR-ABL transcript types (e13a2, n=447; e14a2, n=491; e13a2 and e14a2, n=166) were included in the randomized German CML study IV and treated with an imatinib based therapy consisting of imatinib 400 mg, imatinib 800 mg and combinations of standard dose imatinib with interferon alpha and low-dose cytarabine. The type of BCR-ABL transcript was defined by multiplex PCR. BCR-ABL expression was determined by quantitative RT-PCR and standardized according to the international scale (IS). Cytogenetic response was determined by conventional metaphase analyses. Response landmarks were defined according to European LeukemiaNet criteria, MR 4 was defined as BCR-ABL IS \u2264 0.01% Results: No differences regarding age, sex and Euro risk were observed. A significant difference was observed comparing white blood cells (90,400/\u03bcl vs. 69,100/\u03bcl, p<0.001) and platelets (293,000/\u03bcl vs. 424,000/\u03bcl, p<0.001) at diagnosis (median, e13a2 vs. e14a2, respectively) indicating a distinct phenotype. No significant difference was observed regarding spleen size, basophils, eosinophils, blasts or adverse events under imatinib. Molecular response as determined by a transcript independent quantitative PCR assay was superior in e14a2 patients as compared to e13a2 patients (median time to major molecular response, MMR 1.5 years vs. 1.2 years, p<0.001; median time to MR 4 4.2 years vs. 2.5 years, p<0.001). No difference was observed with regard to the achievement of a complete cytogenetic remission (CCyR). The superior molecular response rate of e14a2 patients did not translate into differences in progression free survival (PFS) or overall survival (OS). Conclusion: Distinct initial blood counts suggest a different phenotype of e13a2 and e14a2 driven CML. MMR and MR 4 are achieved earlier by e14a2 patients whereas no difference was observed with regard to PFS and OS. Disclosures: Schnittger: Mu\u0308nchner Leuka\u0308mie Labor: Equity Ownership. Haferlach: Mu\u0308nchner Leuka\u0308mie Labor: Equity Ownership. German CML Study Group: Deutsche Krebshilfe: Research Funding; Novartis: Research Funding; BMBF: Research Funding; EU: Research Funding; Roche: Research Funding; Essex: Research Funding."
}